M. Coory
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
M. Coory has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
D. Gill
School of Population Health, University of Queensland and 2Clinical Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
1 shared publication
Latest Publications
- 29 December 2008
- Published by Wiley in Internal Medicine Journal
- Vol. 38 (12) , 921-924
Decreasing mortality from non‐Hodgkin lymphoma in Australia
Based on the number of new cases (incidence), non‐Hodgkin lymphoma is an increasingly common cancer in Australia and many developed countries. Until recently, mortality trends have been stable or slightly increasing. However, since the year 2000, mortality has decreased every year by an average of 5.1% per year (95% confidence interval (CI) −7.1 to −3.1%), whereas incidence has continued to increase at 0.9% per year (95%CI 0.6 to 1.2%). It was not possible with the population‐based registry data available to us to untangle the causes of the decrease in mortality. The stable mortality rates during the 1990s (in the face of increasing incidence) might have been because of introduction of novel therapies such as autologous stem cell transplant for relapsed diffuse large cell lymphoma or the purine analogue‐based therapy for indolent lymphomas. A plausible explanation for the large decrease in mortality since 2000 is the introduction of the monoclonal antibody rituximab.
- 29 December 2008
- Published by Wiley in Internal Medicine Journal
- Vol. 38 (12) , 921-924
Decreasing mortality from non‐Hodgkin lymphoma in Australia
Based on the number of new cases (incidence), non‐Hodgkin lymphoma is an increasingly common cancer in Australia and many developed countries. Until recently, mortality trends have been stable or slightly increasing. However, since the year 2000, mortality has decreased every year by an average of 5.1% per year (95% confidence interval (CI) −7.1 to −3.1%), whereas incidence has continued to increase at 0.9% per year (95%CI 0.6 to 1.2%). It was not possible with the population‐based registry data available to us to untangle the causes of the decrease in mortality. The stable mortality rates during the 1990s (in the face of increasing incidence) might have been because of introduction of novel therapies such as autologous stem cell transplant for relapsed diffuse large cell lymphoma or the purine analogue‐based therapy for indolent lymphomas. A plausible explanation for the large decrease in mortality since 2000 is the introduction of the monoclonal antibody rituximab.